LDC and Johnson & Johnson to fast-track promising drug candidates

A collaboration to identify and accelerate drug candidates for the treatment and prevention of diseases with high unmet medical needs has been revealed by Lead Discovery Center (LDC) and Johnson & Johnson Innovation.

Over a two-year period, LDC and Johnson & Johnson’s London Innovation Centre will identify translational research opportunities sourced from LDC’s top-tier academic network, including institutes from the Max Planck Society, the Helmholtz Association and various universities. Johnson & Johnson Innovation will review and evaluate the opportunities with the objective of establishing drug discovery collaborations with LDC in selected projects that are aligned with the company’s therapeutic focus areas.

“Through our academic network, we have access to a broad range of exciting molecular targets, pathobiological mechanisms and new therapeutic approaches which are the basis for project proposals with a high innovation potential for drug discovery,” said Dr. Bert Klebl, CEO of the LDC. “Together with Johnson & Johnson Innovation, we will now be able to offer a solution for more of our academic partners to translate their innovative findings into benefit for patients.”

For each project selected by Johnson & Johnson Innovation, the partners will negotiate a collaboration agreement for its joint development at the LDC up to the next mutually agreed milestone. The details regarding financial provisions and research activities will be agreed on a project-by-project basis to ensure a fair balance of investments and potential returns between the partners. Any revenue received from commercialization will be shared with the academic inventors and collaborating institutions.